IMPACT OF GOLIMUMAB ON PHYSICAL FUNCTION AND EMPLOYABILITY OF PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM 3 PHASE III CLINICAL TRIALS

被引：0
|
作者：
Han, C. [1 ]
Keystone, E. [2 ]
Fleischmann, R. [3 ]
Smolen, J. [4 ,5 ]
Matteson, E. L. [6 ]
Emery, P. [7 ,8 ]
Genovese, M. [9 ]
Gathany, T. [1 ]
Hsia, E. C. [10 ,11 ]
机构：
[1] Johnson & Johnson Pharmaceut Serv LLC, Malvern, PA USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[4] Med Univ Vienna, Vienna, Austria
[5] Hietzing Hosp, Vienna, Austria
[6] Mayo Clin, Rochester, NY USA
[7] Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
[8] Univ Leeds, Leeds, W Yorkshire, England
[9] Stanford Univ, Palo Alto, CA 94304 USA
[10] Janssen Res & Dev LLC, Spring House, PA USA
[11] Univ Penn, Philadelphia, PA 19104 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.2535
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0156
引用
收藏
页码：234 / 234
页数：1
相关论文
共 50 条
  • [41] Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Kay, Jonathan
    Fleischmann, Roy
    Keystone, Edward C.
    Hsia, Elizabeth C.
    Goldstein, Neil
    Hsu, Benjamin
    Zhou, Yiying
    Braun, Juergen
    Kavanaugh, Arthur
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S198 - S199
  • [42] IMPACT OF CLINICAL REMISSION ON PHYSICAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ALX-0061: POST-HOC ANALYSIS OF PHASE I/II DATA
    Van Beneden, K.
    Verschueren, K.
    Willems, W.
    Wouters, H.
    D'Artois, J.
    De Swert, K.
    Arold, G.
    De Bruyn, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 506 - 506
  • [43] GOLIMUMAB 5-YEAR SAFETY: AN ANALYSIS OF POOLED DATA FROM THE LONG TERM EXTENSIONS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
    Kay, J.
    Fleischmann, R.
    Keystone, E.
    Hsia, E. C.
    Goldstein, N.
    Hsu, B.
    Zhou, Y.
    Braun, J.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 241 - 242
  • [44] Associations Among Fatigue, Vitality, Sleep, and HRQL in Patients with Rheumatoid Arthritis: Data from Phase 3 Trials of Tofacitinib
    Bartlett, Susan
    Bingham, Clifton
    van Vollenhoven, Ronald
    Murray, Christopher
    Gruben, David
    Hsu, Ming-Ann
    Gold, David
    Cella, David
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1134 - 1134
  • [45] EFFICACY AND SAFETY OF UPADACITINIB IN TNFI-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS
    Fleischmann, R. M.
    Bessette, L.
    Sparks, J.
    Hall, S.
    Jain, M.
    Kakehasi, A.
    Song, Y.
    Meerwein, S.
    Demasi, R.
    Suboticki, J.
    Rubbert-Roth, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 618 - 619
  • [46] Efficacy and safety of upadacitinib in TNFi-IR patients with rheumatoid arthritis from three Phase 3 clinical trials
    Fleischmann, Roy
    Bessette, Louis
    Sparks, Jeffrey
    Hall, Stephen
    Jain, Manish
    Kakehasi, Adriana
    Song, Yanna
    Meerwein, Sebastian
    DeMasi, Ryan
    Suboticki, Jessica
    Rubbert-Roth, Andrea
    SWISS MEDICAL WEEKLY, 2022, 152 : 14S - 16S
  • [47] EFFECTS OF SMOKING ON BARICITINIB EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED ANALYSIS FROM TWO PHASE 3 CLINICAL TRIALS
    Curtis, J.
    Emery, P.
    Burmester, G.
    Arora, V.
    Alam, J.
    Muram, D.
    Klareskog, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 244 - 244
  • [48] Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials
    Fleischmann, Roy
    Bessette, Louis
    Sparks, Jeffrey
    Hall, Stephen
    Jain, Manish
    Kakehasi, Adriana
    Song, Yanna
    Meerwein, Sebastian
    DeMasi, Ryan
    Suboticki, Jessica
    Rubbert-Roth, Andrea
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 541 - 543
  • [49] FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS ANTI-TUMOR NECROSIS FACTOR THERAPY
    Smolen, Josef S.
    Kay, Jonathan
    Landewe, Robert
    Matteson, Eric K.
    Gaylis, Norman
    Wollenhaupt, J.
    Murphy, Frederick T.
    Han, Chenglong
    Gathany, Tim
    Xu, Stephen
    Zhou, Yiying
    Hsia, Elizabeth C.
    Doyle, Mittie K.
    RHEUMATOLOGY, 2014, 53 : 87 - 88
  • [50] Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
    Smolen, Josef S.
    Kay, Jonathan
    Landewe, Robert
    Matteson, Eric L.
    Gaylis, Norman B.
    Wollenhaupt, Juergen
    Murphy, Frederick T.
    Han, Chenglong
    Gathany, Timothy A.
    Xu, Stephen
    Zhou, Yiying
    Hsia, Elizabeth C.
    Doyle, Mittie K.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S991 - S991
12345